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Introduction 
Angiotensin receptor blockers (ARBs) such as Losartan 
and Telmisartan (Figure 1) are potent chemicals, which 
antagonize angiotensin II (Ang II) by preventing Ang II 
from  binding  to  Ang  II  receptor  (AT1)  on  vascular 
smooth muscle.  As a result, blood vessels dilate and 
blood pressure is reduced. The vasodilatation actions of 
ARBs are due to reduced concentration of intracellular 
Ca
+2 ions.
1 
On  the  other  hand,  1,4-dihydropyridines  (DHP) 
containing substituted heterocycles on the C4 position, 
such as Nifedipine,
2-8 have shown to reduce the influx 
of extracellular Ca
+2 ions through the L-type potential-
dependent  calcium  channel  therefore  reducing  the 
hypertension.
1Arun  et  al.  have  demonstrated  that 
Nifedipine  was  able  to  vasodilate  the  contraction  of 
thoracic aorta isolated from diabetic rats
9 induced by the 
Angiotensin II.  The vazodilation of thoractic aorta was 
concluded  to  be  due  to  enhanced  functional  coupling 
between  AT1  receptors  and  DHP-sensitive  L-type 
calcium channels.  
A B S T R A C T  A R T I C L E  I N F O                            
Introduction:  We  report  the  synthesis  of  novel  1,4-dihydropyridine  derivatives 
containing  biphenyl-2'-tetrazole  moieties.  We  hypothesized  that  merging  the  key 
structural elements present in an AT1 receptor antagonist with key structural elements in 
1,4-dihydropyridine calcium channel blockers would yield novel analogs with potential 
dual activity for both receptors. This strategy led to the design and synthesis of dialkyl 
1,4-dihydro-2,6-dimethyl-4-[2-n-alkyl-1-[2΄-(1H-tetrazole-5-yl) biphenyl -4-yl] methyl] 
imidazole-4(or 5)-yl]- 3, 5-pyridinedicarboxylate analogs. Methods: These compounds 
were  obtained  by  two  methods  starting  from  biphenyltetrazolyl-4-(or  5)-
imidazolecarboxaldehyde intermediates employing in classical Hantzsch condensation 
reaction. In the first method, triphenylmethyl protecting group of 4- or 5-carboxaldehyde 
intermediate was first removed in acidic media and then classical Hantzsch reaction was 
employed in order to obtain the final products. In the second method, without further 
deprotection process, protected 4- or 5-carboxaldehyde intermediate directly was used in 
Hantzsch reaction. Results: The second method was more efficient than the first method 
since  the  deprotection  and  ring  closure  reaction  occurs  simultaneously  in  one  pot. 
Conclusion:  Eight  novel  dihydropridines  analogs  were  synthesized  using  classic 
Hantzsch  condensation  reaction.  Chemical  structures  of  the  compounds  were 
characterized by 
1H NMR, infrared and mass spectroscopy. 
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We have hypothesized that merging the key structural 
elements present in an AT1 receptor antagonists such as 
[2΄-(acidic  moiety)biphenyl-4-yl]  imidazole 
pharmacophores  with  key  structural  elements  in  1,4-
dihydropyridine calcium channel blockers would yield 
compounds  with  potential  dual  activity  for  both 
receptors. Advantages of combination therapy of ARBs 
and  CCBs  which  include  low  dose,  low  side  effect, 
cardioprotection, renoprotection and anti-atherosclerosis 
are reported in literatures.
10-12 
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Figure 1. Chemical structure of nifedipine, losartan and designed dual CCB-ARB (compounds 5, 7 and 8) 
 
 
 
 
In the previous work, this strategy led to the design and 
synthesis of novel 4-[2΄-(carboxylic acid)biphenyl-4-yl] 
imidazolyl-1,4-dihydropyridine-3,5-dicarboxylates  as 
potential  dual  acting  angiotensin  II  inhibitors  and 
calcium channel blockers.
13 Recently, Hadizadeh et al. 
have also reported the synthesis and activity studies of 
novel dihydropyridines containing methyl biphenyl -2'-
caboxylic  acid  moieties.  Among  the  synthesized 
analogs,  compounds  8a  and  8b  (Figure  1)  showed  to 
have both calcium channel and AT1 receptor blocking 
activities. Their effects on AT1 receptors are 1000 and 
100,000 times more than losartan respectively.
14 Herein, 
we  report  the  design  and  synthesis  of  novel  4-[[2΄-
(tetrazole-5-yl)biphenyl-4-yl]  imidazol-4  or  5-yl]-1,4-
dihydropyridine-3,5-dicarboxylates (5 and 7) (Figure 1). 
These analogs were synthesized, first by N
1-alkylation 
of  2-alkylimidazole-4(5)-carboxaldehydes  (1)  with 
tritylated  4΄-(bromomethyl)  biphenyl-2-yl]  tetrazole  to 
afford compounds 2 and 3. Then, using two methods, 
compounds  2  and  3  were  subjected  to  Hantzsch 
condensation  reactions
13-15  to  obtain  final 
dihydropyridine products in moderately yields. 
 
Materials and methods   
N-(triphenylmethyl-5-[4΄-(bromomethyl) biphenyl-2-yl] 
tetrazole was purchased from Sinosource Pharma Ltd. 
(Hengsha Guangzhou, China). 2-Alkyl-imidazole-4(5)-
carboxaldehyde1  was  prepared  according  to  the 
literature.
13,16,17  Other  chemicals  were  purchased  from  
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Merck  Chemical  Company  (Darmstadt,  Germany). 
Melting  points  were  determined  by  a  Gallenkamp 
capillary  apparatus  and  are  uncorrected. 
1H  NMR 
spectra  were  obtained  with  a  Bruken-Spectrospin  200 
MHz spectrometer. (Varian, Switzerland).  
Tetramethylsilane  was  used  as  an  internal  standard. 
Mass spectra were obtained using a Finnigan Mat TSQ-
70  spectrometer  at  70  eV  (Finnigan  Mat,  Bremen, 
Germany).  The  FT-IR  spectrum  was  recorded  on  a 
Shimadzu FTIR 4300 spectrometer (Potassium bromide 
disks)  (Shimadzu,  Kyoto,  Japan).  The  purity  of 
compounds  was  confirmed  by  TLC  using  different 
mobile phases. Elemental analyses were carried out on a 
Heraeus  CHN-O  rapid  elemental  analyzer  (Heraeus 
GmbH, Germany) for C, H, and N and the results are 
within ± 0.4% of the theoretical values. 
2-n-Propyl-1-[[2΄-[(triphenylmethyl)  tetrazole-5-yl] 
biphenyl -4-yl] methyl] imidazole-4(5)-carboxaldehyde 
(2a, 3a) 
To  a  solution  of  2-propyl-imidazole-4(5)-
carboxaldehyde1a  (5  g,  33  mmoles,  1  eq.)  in  dry 
dimethylformamide (90 mL), was added K2CO3 (9.1 g, 
66 mmoles, 2 eq.) and the reaction mixture was stirred 
at  room  temperature  for  30  minutes.  Then  N-
(triphenylmethyl-5-[4΄-(bromomethyl)  biphenyl-2-yl] 
tetrazole  (20  g,  73  mmoles,  1.1  eq.)  was  added  and 
stirring  continued  for  24  hours.  The  reaction  mixture 
was  filtered  and  solvents  removed  under  reduced 
pressure. To the residue was added water (30 mL) and 
extracted  with  ethyl  acetate.  The  organic  phase  was 
dried  over  anhydrous  sodium  sulfate  and  solvents 
removed  to  give  a  viscous  material.  Column 
chromatography  using  toluene/ethyl  acetate(80:20)  as 
eluent  afforded  2.84  g  (13.5  %)  of    2-propyl-1-[[2΄-
(triphenylmethyl)  tetrazole-5-yl]biphenyl  -4-
yl]methyl]imidazole-5-carboxaldehyde  (3a) 
(regioisomer of lower Rƒ value) and 5.2 g (23 %) of 2-
propyl-1-[[2΄-[(triphenylmethyl) tetrazole-5-yl]biphenyl 
-4-yl]methyl]imidazole-4-carboxaldehyde  (2a) 
(regioisomer of higher Rƒ value). 
2a: mp: 128 – 130 °C, ir (potassium bromide)  3050 
(C-H, aromatic), 2964 (C-H, aliphatic), 1685 cm
-1 (C = 
O). 
1H NMR (deuteriochloform)  9.81 (S, 1H, CHO), 
8.03 (dd, 1H, J3',4' =6 , J3',5' =2.1 Hz, H-3'  phenyl), 7.52-
7.25 (m, 12H, H aromatic), 7.24 (d, 2H, J=8.2 Hz, H-2,6 
phenyl),  6.98  (dd,  6H,  J2'',3''  =6.1,  J2'',4''  =1.7  Hz,  H 
orthotrityl), 6.93 (d, 2H, J=8.4 Hz, H-3,5 phenyl), 5.00 
(s,  2H,  NCH2),  2.68  (t,  2H,  J=7.4Hz,  CH3CH2CH2), 
1.90–1.72  (m,  2H,  CH2),  1.03  ppm  (t,  3H,  J=7.3Hz, 
CH3). 
3a: mp: 144 – 146°C, ir (potassium bromide)  3050 
(C-H,  aromatic),  2964  (C-H,  aliphatic),  1666  cm
-1 
(C=O). 
1H  NMR  (deuteriochloform)    9.69  (S,  1H, 
CHO), 8.15 (dd, 1H, J3',4' =6 , J3',5' =2 Hz, H-3'  phenyl), 
7.81  (s,  1H,  H  imidazole),  7.53-7.25  (m,  12H,  H 
aromatic), 7.14 (d, 2H, J=8.3 Hz, H-2,6 phenyl), 6.99 
(dd, 6H, J2'',3'' =6.1, J2'',4'' =1.3 Hz, H orthotrityl), 6.88 (d, 
2H, J=8.4 Hz, H-3,5 phenyl), 5.44 (s, 2H, NCH2), 2.60 
(t,  2H,  J=7.3  Hz,  CH3CH2CH2),  1.85–1.63  (m,  2H, 
CH2), 0.97 ppm (t, 3H,  =7.3 Hz, CH3). 
2-n-Butyl-1-[[2΄-[(triphenylmethyl)  tetrazole-5-yl] 
biphenyl -4-yl] methyl] imidazole-4(5)-carboxaldehyde 
(2b, 3b). 
These  compounds  were  prepared  by  the  method 
described for (2a, 3a). 
2b: mp: 134-136 °C, ir (potassium bromide)  3050 (C-
H, aromatic), 2958 (C-H, aliphatic), 1605 cm
-1 (C=O). 
1H NMR (deuteriochloform)  9.81(s, 1H, CHO), 8.04 
(dd,  1H,  J3',4'=6.6,  J3',5'=3  Hz,  H-3'  phenyl),  7.56-7.23 
(m,  12H,  H  aromatic),  7.21(d,  2H,  J=8.2  Hz,  H-2,6 
phenyl), 6.97 (dd, 6H,J2'',3''=6, J2'',4''=1 Hz, H orthotrityl), 
6.85  (d,  2H,  J=8.4  Hz,  H-3,5  phenyl),  5.00  (s,  2H, 
NCH2), 2.71 (t, 2H, J=7.5 Hz, CH3CH2CH2CH2), 1.84-
1.24 (m, 4H, CH2), 0.98 ppm (t, 3H, J=7.2 Hz, CH3). 
3b: mp: 148-150 °C, ir (potassium bromide)  3050 (C-
H, aromatic), 2950 (C-H, aliphatic), 1672 cm
-1 (C=O). 
1H NMR (deuteriochloform)  9.69 (S, 1H, CHO), 7.97 
(dd, 1H, J3',4' =6.6, J3',5' =3 Hz, H-3  phenyl), 7.82 (s, 1H, 
H imidazole), 7.57-7.25 (m, 12H, H aromatic), 7.14 (d, 
2H,  J=8.2  Hz,  H-2,6  phenyl),  6.97  (dd.  6H,  J2'',3''=  8, 
J2",4''= 1.1 Hz, H orthotrityl), 6.77 (d, 2H, J=8.4 Hz, H-
3,5 phenyl), 5.51 (s, 2H, NCH2), 2.62 (t, 2H, J=7.3 Hz, 
CH3CH2CH2CH2), 1.77 – 1.27 (m, 4H, CH2), 0.93 ppm 
(t, 3H, J=7.2 Hz, CH3). 
First method: removal of protective trityl group and 
then dihydropyridine ring closure. 
2-n-Propyl-1-[[2΄-(1H-tetrazole-5-yl)  biphenyl  -4-yl] 
methyl] imidazole-4-carboxaldehyde (4a) 
A solution of 2a (2.32 g, 3.8 mmoles) in a mixture of 
tetrahydrofuran (55 mL) and 10% HCl (27.5 mL) was 
stirred at 25°C for 4 hours. To the reaction mixture, 30 
mL  of  10%  sodium  hydroxide  was  added  and  the 
solvents removed under vacuum. Then water was added 
to the residue and filtered. Finally pH of the filtrate was 
adjusted to 3-4 and filtered again to separate 4a (1.01 g, 
71%). 
Compounds 4b, 6a and 6b were prepared according to 
the  method  described  for  4a  with  the  69%,  82%  and 
65% yields respectively. The crude product was used in 
the  Hantzsch  reaction  to  provide  dihydropyridine 
compounds (5a-d and 7a-d). 
Dimethyl  1,  4-dihydro-2,  6-dimethyl-4-[2-n-propyl-1-
[2΄-(1H-tetrazole-5-yl)  biphenyl  -4-yl]  methyl] 
imidazole-4-yl]-3,5-pyridinedicarboxylate (5a) 
A  solution  of  4a  (0.52  g,  1.2  mmoles,  1eq.),  methyl 
acetoacetate (0.3 g, 2.6 mmoles, 2.2 eq.) and ammonium 
hydroxide  25%  (0.4  mL)  in  methanol  (4.8  mL)  was  
4    |  Advanced Pharmaceutical Bulletin, 2011, 1(1), 1-9  Copyright © 2011 by Tabriz University of Medical Sciences 
Shahbazi Mojarrad et al. 
protected from light and stirred at 25 °C for 30 minutes 
and then refluxed overnight. The solvent was removed 
under  vacuum  and  then  purified  with  column 
chromatography (elution: chloroform-methanol 95:5) to 
provide 5a in (0.35 g) 44% yield with mp 148 – 150 °C; 
IR  (potassium  bromide)    3417  (N-H),  3050  (C-H, 
aromatic), 2950 (C-H, aliphatic), 1695 (C=O), 1498 cm
-
1 (C=C, aromatic). 
1H NMR (DMSO-d6)  9.09 (br s, 
1H, NH), 7.61–7.39 (m, 4H, H aromatic), 7.09 (d, 2H, 
J=8 Hz, H-2,6 phenyl), 6.98 (d, 2H, J=8.2 Hz, H-3,5 
phenyl), 6.80 (s, 1H, H imidazole), 5.12 (s, 2H, NCH2), 
4.88 (s, 1H, HC4 DHP), 3.55 (s, 6H, OCH3), 2.61 (t, 2H, 
J=7 Hz, CH3CH2CH2), 2.22 (s, 6H, CH3 DHP), 1.51–
1.40 (m, 2H, CH2), 0.85 ppm (t, 3H, J=7.1 Hz, CH3). 
ms: m/z (%) 524 (2), 286 (31), 373 (2), 358 (14), 288 
(33), 252 (27), 229 (34), 192 (100), 165 (61), 134 (67), 
96 (89), 45 (57). Anal.calcd. for C31H33N7O4: C, 65.59; 
H, 5.86; N, 17.27. Found: C, 65.72; H, 5.99; N, 17.02. 
Diethyl 1, 4-dihydro-2, 6-dimethyl-4-[2-n-propyl-1-[2΄-
(1H-tetrazole-5-yl) biphenyl -4-yl] methyl] imidazole-4-
yl] -3,5-pyridinedicarboxylate (5b) 
A  solution  of  4a  (0.48  g,  1.3  mmoles),  ethyl 
acetoacetate  (0.37  g,  2.9  mmoles)  and  ammonium 
hydroxide  25%  (0.42  mL)  in  ethanol  (5.2  mL)  was 
reacted  according  to  the  method  described  for  4a. 
Purification  was  done  with  column  chromatography 
(elution:  chloroform-methanol  95:5)  to  afford  5b  in 
(0.32 g) 42% yield with mp 149 – 151 °C; 
IR  (potassium  bromide)    3450  (N-H),  3050  (C-H, 
aromatic), 2974 (C-H, aliphatic), 1685 (C=O), 1498 cm
-
1 (C=C, aromatic). 
1H NMR (DMSO-d6)  8.99 (br s, 
1H, NH), 7.62–7.39 (m, 4H, H aromatic), 7.09 (d, 2H, 
J=8.2 Hz, H-2,6 phenyl), 7.01 (d, 2H, J=8.4 Hz, H-3,5 
phenyl), 6.84 (s, 1H, H imidazole), 5.15 (s, 2H, NCH2), 
4.88 (s, 1H, HC4 DHP), 4.11–3.93 (m, 4H, OCH2), 2.64 
(t, 2H, J=7.4 Hz, CH3CH2CH2), 2.22 (s, 6H, CH3 DHP), 
1.51–1.40  (m,  2H,  CH2),  1.14  (t,  6H,  J=7.1  Hz, 
OCH2CH3), 0.84 ppm (t, 3H, J=7.3 Hz, CH3). ms: m/z 
(%) 373 (6), 302 (14), 272 (18), 251 (33), 206 (66), 225 
(47),  192  (100),  178  (86),  165  (54).  Anal.calcd.  for 
C33H37N7O4:  C,  66.54;  H,  6.26;  N,  16.46.  Found:  C, 
66.45; H, 6.53; N, 16.59. 
Dimethyl  1,  4-dihydro-2,  6-dimethyl  -4-[2-n-butyl-1-
[[2΄-(1H-tetrazole-5-yl)  biphenyl  -4-yl]  methyl] 
imidazole-4-yl] -3,5-pyridinedicarboxylate (5c) 
A  solution  of  4b  (0.50  g,  1.3  mmoles),  methyl 
acetoacetate  (0.35  g,  3  mmoles)  and  ammonium 
hydroxide  25%  (0.50  mL)  in  methanol  (5  mL)  was 
reacted  according  to  the  method  described  for  5a. 
Purification  was  done  with  column  chromatography 
(elution:  chloroform-methanol  95:5)  to  afford  5c  in 
(0.14  g)  19%  yield  with  mp  153  –  155  °C;  IR 
(potassium  bromide)    3411  (N-H),  3064  (C-H, 
aromatic), 2954 (C-H, aliphatic), 1693 (C=O), 1500cm
-
1(C=C,  aromatic). 
1H  NMR  (DMSO-d6)    9.14  (br  s, 
1H, NH), 7.63 – 7.47 (m, 4H, H aromatic), 7.10 (d, 2H, 
J=8.3 Hz, H-2,6 phenyl), 6.99 (d, 2H, J=8.3 Hz, H-3,5 
phenyl), 6.87 (s, 1H, H imidazole), 5.11 (s, 2H, NCH2), 
4.88 (s, 1H, HC4 DHP), 3.56 (s, 6H, OCH3), 2.61 (t, 2H, 
J=8 Hz, CH3CH2CH2), 2.22 (s, 6H, CH3 DHP), 1.46–
1.14 (m, 4H, CH2), 0.83 ppm (t, 3H, J=7.3 Hz, CH3). 
ms: m/z (%) 372 (10), 330 (24), 273 (11), 252 (6), 223 
(34),  192  (100),  165  (79),  134  (81).  Anal.calcd.  for 
C32H35N7O4:  C,  66.07;  H,  6.06;  N,  16.86.  Found:  C, 
65.93; H, 6.32; N, 16.70. 
Diethyl 1, 4-dihydro-2, 6-dimethyl-4-[2-n-butyl-1-[[2΄-
(1H-tetrazole-5-yl) biphenyl -4-yl] methyl] imidazole-4-
yl] -3, 5-pyridinedicarboxylate (5d) 
A  solution  of  4b  (0.51  g,  1.3  mmoles),  ethyl 
acetoacetate  (0.38  g,  2.9  mmoles)  and  ammonium 
hydroxide 25% (0.5 mL) in ethanol (5 mL) was reacted 
according to the method described for 5a. Purification 
was  done  with  column  chromatography  (elution: 
chloroform-methanol 95:5) to afford 5d in (0.31 g) 38% 
yield with mp 154 – 156 °C; IR (potassium bromide)  
3386  (N-H),  3050  (C-H,  aromatic),  2.964  (C-H, 
aliphatic), 1685 (C=O), 1496 cm
-1 (C=C, aromatic). 
1H 
NMR (DMSO-d6)  8.88 (br s, 1H, NH), 7.62–7.39 (m, 
4H, H aromatic), 7.09 (d, 2H, J=8.2 Hz, H-2,6 phenyl), 
7.00 (d, 2H, J=8.2 Hz, H-3,5 phenyl), 6.82 (s, 1H, H 
imidazole), 5.14 (s, 2H, NCH2), 4.88 (s, 1H, HC4 DHP), 
4.11–3.88  (m,  4H,  OCH2),  2.61  (t,  2H,  J=8.2  Hz, 
CH2CH2CH2), 2.21 (s, 6H, CH3 DHP), 1.41–1.20 (m, 
4H, CH2), 1.15 (t, 6H, J=7.1 Hz, OCH2CH3), 0.82 ppm 
(t, 3H, J=7.3 Hz, CH3). ms: m/z (%) 387 (9), 359 (5), 
316 (13), 278 (13), 251 (20), 206 (72), 179 (100), 165 
(28). Anal.calcd. for C34H39N7O4: C, 66.97; H, 6.45; N, 
16.08. Found: C, 66.12; H, 6.61; N, 16.28. 
Dimethyl  1,  4-dihydro-2,  6-dimethyl-4-[2-n-propyl-1-
[2΄-(1H-tetrazole-5-yl)  biphenyl  -4-yl]  methyl] 
imidazole-5-yl]-3,5-pyridinedicarboxylate (7a) 
A  solution  of  6a  (0.15  g,  0.4  mmoles),  methyl 
acetoacetate  (0.10  g,  0.90  mmoles)  and  ammonium 
hydroxide  25%  (0.10  mL)  in  methanol  (2  mL)  was 
reacted  according  to  the  method  described  for  5a. 
Purification  was  done  with  column  chromatography 
(elution:  chloroform-methanol  95:5)  to  afford  7a  in 
(0.11 g) 48% yield with mp 174 – 176°C; 
IR  (potassium  bromide)    3400  (N-H),  3046  (C-H, 
aromatic), 2950 (C-H, aliphatic), 1680 (C=O), 1490 cm
-
1 (C=C, aromatic). 
1H NMR (DMSO-d6)  9.16 (br s, 
1H, NH), 7.59–7.38 (m, 4H, H aromatic), 7.07 (d, 2H, 
J=8.2 Hz, H-2,6 phenyl), 6.73 (d, 2H, J=8 Hz, H-3,5 
phenyl), 6.49 (s, 1H, H imidazole), 5.26 (s, 2H, NCH2), 
4.91 (s, 1H, HC4 DHP), 3.36 (s, 6H, OCH3), 2.33 (t, 2H,  
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J=7.4 Hz, CH3 CH2CH2), 2.17 (s, 6H, CH3 DHP), 1.53–
1.41 (m, 2H, CH2), 0.81 ppm (t, 3H, J=7.3 Hz, CH3). 
ms: m/z (%), 358 (6), 300 (6), 252 (12), 232 (13), 223 
(20),  192  (81),  178  (87),  165  (100).  Anal.calcd.  for 
C31H33N7O4:  C,  65.59;  H,  5.86;  N,  17.27.  Found:  C, 
65.77; H, 6.04; N, 17.38. 
Diethyl 1, 4-dihydro-2, 6-dimethyl-4-[2-n-propyl-1-[2΄-
(1H-tetrazole-5-yl) biphenyl -4-yl] methyl] imidazole-5-
yl]-3, 5-pyridinedicarboxylate (7b) 
A  solution  of  6a  (0.22  g,  0.59  mmoles),  ethyl 
acetoacetate  (0.17  g,  1.3  mmoles)  and  ammonium 
hydroxide  25%  (0.  20  mL)  in  ethanol  (2.5  mL)  was 
reacted  according  to  the  method  described  for  5a. 
Purification  was  done  with  column  chromatography 
(elution:  chloroform-methanol  95:5)  to  afford  7b  in 
(0.15  g)  43%  yield  with  mp  170  –  172  °C;  IR 
(potassium  bromide)    3450  (N-H),  3050  (C-H, 
aromatic), 2974 (C-H, aliphatic), 1676 (C=O), 1496cm
-1 
(C=C, aromatic). 
1H NMR (DMSO-d6)  9.08 (br s, 1H, 
NH), 7.70–7.40 (m, 4H, H aromatic), 7.05 (d, 2H, J=8.2 
Hz,  H-2,6  phenyl),  6.75  (d,  2H,  J=8.3  Hz,  H-3,5 
phenyl), 6.52 (s, 1H, H imidazole), 5.26 (s, 2H, NCH2), 
5.01 (s, 1H, HC4 DHP), 3.98–3.75 (m, 4H, OCH2), 2.32 
(t, 2H, J=7.4 Hz, CH3CH2CH2), 2.13 (s, 6H, CH3 DHP), 
1.49–1.29  (m,  2H,  CH2),  1.08  (t,  6H,  J=7  Hz, 
OCH2CH3), 0.79 ppm (t, 3H, J=7.4 Hz, CH3). ms: m/z 
(%) 595 [M
++1] (2), 300 (5), 252 (10), 225 (20), 207 
(38), 78 (25), 46 (100). Anal.calcd. for C33H37N7O4: C, 
66.54; H, 6.26; N, 16.46. Found: C, 66.76; H, 6.21; N, 
16.53. 
Dimethyl  1,  4-dihydro-2,  6-dimethyl-4-[2-n-butyl-1-
[[2΄-(1H-tetrazole-5-yl)  biphenyl  -4-yl]  methyl] 
imidazole-5-yl]-3, 5-pyridinedicarboxylate (7c). 
A  solution  of  6b  (0.36  g,  0.93  mmoles),  methyl 
acetoacetate  (0.23  g,  2.05  mmoles)  and  ammonium 
hydroxide  25%  (0.30  mL)  in  methanol  (4  mL)  was 
reacted  according  to  the  method  described  for  5a. 
Purification  was  done  with  column  chromatography 
(elution:  chloroform-methanol  95:5)  to  afford  7c  in 
(0.28  g)  52%  yield  with  mp  156  –  158  °C;  IR 
(potassium  bromide)    3442  (N-H),  3050  (C-H, 
aromatic), 2958 (C-H, aliphatic), 1704 (C=O), 1496cm
-1 
(C=C, aromatic). 
1H NMR (DMSO-d6)  9.19 (br s, 1H, 
NH), 7.62–7.43 (m, 4H, H aromatic), 7.07 (d, 2H, J= 7.5 
Hz, H-2,6 phenyl), 6.78 (d, 2H, J=8 Hz, H-3,5 phenyl), 
6.58 (s, 1H, H imidazole), 5.32 (s, 2H, NCH2), 4.95 (s, 
1H, HC4 DHP), 3.38 (s, 6H, OCH3), 2.38 (t, 2H, J=7.2 
Hz, CH3CH2CH2), 2.18 (s, 6H, CH3 DHP), 1.44–1.11 
(m, 4H, CH2), 0.77 ppm (t, 3H, J=7.2 Hz, CH3). ms: m/z 
(%) 582 (4), 535 (12), 347 (11), 314 (12), 249 (14), 221 
(28),  192  (100),  178  (95),  165  (54).  Anal.calcd.  for 
C32H35N7O4:  C,  66.07;  H,  6.06;  N,  16.86.  Found:  C, 
66.31; H, 5.98; N, 16.95. 
Diethyl 1, 4-dihydro-2, 6-dimethyl-4-[2-n-butyl-1-[[2΄-
(1H-tetrazole-5-yl) biphenyl -4-yl] methyl] imidazole-5-
yl]-3, 5-pyridinedicarboxylate (7d) 
A  solution  of  6b  (0.36  g,  0.93  mmoles),  ethyl 
acetoacetate  (0.26  g,  2.05  mmoles)  and  ammonium 
hydroxide 25% (0.3 mL) in ethanol (4 mL) was reacted 
according to the method described for 5a. Purification 
was  done  with  column  chromatography  (elution: 
chloroform-methanol 95:5) to afford 7d in (0.27 g) 47% 
yield with mp 150 – 152 °C; IR (potassium bromide) 
3423  (N-H),  3072  (C-H,  aromatic),  2964  (C-H, 
aliphatic), 1677 (C=O), 1492 cm
-1 (C=C, aromatic). 
1H 
NMR (DMSO -d6)  9.16 (br s, 1H, NH), 7.65–7.41 (m, 
4H, H aromatic), 7.05 (d, 2H, J=8.2 Hz, H-2,6 phenyl), 
6.78 (d, 2H, J=8.2 Hz, H-3,5 phenyl), 6.60 (s, 1H, H 
imidazole), 5.31 (s, 2H, NCH2), 5.04 (s, 1H, HC4 DHP), 
3.99–3.76  (m,  4H,  OCH2),  2.38  (t,  2H,  J=7.2  Hz, 
CH3CH2CH2), 2.14 (s, 6H, CH3 DHP), 1.40–1.09 (m, 
4H, CH2), 1.08 (t, 6H, J=7.1 Hz, OCH2CH3), 0.75 ppm 
(t, 3H, J=7.3 Hz, CH3). ms: m/z (%) 287 (6), 252 (10), 
246  (18),  206  (27),  174  (42),  106  (11),  77  (19),  45 
(100). Anal.calcd. for C34H39N7O4: C, 66.97; H, 6.45; N, 
16.08. Found: C, 67.22; H, 6.71; N, 15.81. 
Second method:Dihydropyridine ring closure 
Diethyl  1,  4-dihydro-2,  6-dimethyl-4-[2-n-propyl-1-
[[2΄-(1H-tetrazole-5-yl)  biphenyl  -4-yl]  methyl] 
imidazole-4-yl]-3, 5-pyridinedicarboxylate (5b). 
A  solution  of  2a  (1.2  g,  1.95  mmoles),  ethyl 
acetoacetate  (0.56  g,  4.3  mmoles)  and  ammonium 
hydroxide (0.75 mL) in ethanol (7.5 mL) was protected 
from light and stirred at 25°C for 30 minutes and then 
refluxed over night. The solvents were removed under 
vacuum  and  purification  was  achieved  with  column 
chromatography (elution: chloroform-methanol 95:5) to 
provide 5b in(0.51g) 0.44% yield  with mp 151 – 152 
°C; IR (potassium bromide)  3450 (N-H), 3050 (C-H, 
aromatic), 2974 (C-H, aliphatic), 1685 (C=O), 1498cm
-1 
(C=C, aromatic). 
1H NMR (DMSO-d6)  8.99 (br s, 1H, 
NH), 7.62–7.39 (m, 4H, H aromatic), 7.09 (d, 2H, J=8.2 
Hz,  H-2,6  phenyl),  7.01  (d,  2H,  J=8.4  Hz,  H-3,5 
phenyl), 6.84 (s, 1H, H imidazole), 5.15 (s, 2H, NCH2), 
4.88 (s, 1H, HC4 DHP), 4.11–3.93 (m, 4H, OCH2), 2.64 
(t, 2H, J=7.4 Hz, CH3CH2CH2), 2.22 (s, 6H, CH3 DHP), 
1.51–1.40  (m,  2H,  CH2),  1.14  (t,  6H,  J=7.1  Hz, 
OCH2CH3),  0.84  ppm  (t,  3H,  J=7.3  Hz,  CH3). 
Anal.calcd. for C33H37N7O4: C, 66.54; H, 6.26; N, 16.46. 
Found: C, 66.36; H, 6.06; N, 16.61. 
Dimethyl  1,  4-dihydro-2,  6-dimethyl-4-[2-n-butyl-1-
[[2΄-(1H-tetrazole-5-yl)  biphenyl  -4-yl]  methyl] 
imidazole-4-yl]-3, 5-pyridinedicarboxylate (5c)  
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A  solution  of  2b  (0.81  g,  1.3  mmoles),  methyl 
acetoacetate  (0.37  g,  2.9  mmoles)  and  ammonium 
hydroxide  25%  (0.5  mL)  in  methanol  (5  mL)  was 
reacted  according  to  the  method  described  in  second 
method for compound 5b. Purification  was done  with 
column chromatography (elution: chloroform-methanol 
95:5) to afford 5c in(0.36 g) 34% yield with mp 154 – 
156 °C; IR (potassium bromide)   3411 (N-H), 3064 
(C-H,  aromatic),  2954  (C-H,  aliphatic),  1693  (C=O), 
1500 cm
-1 (C=C, aromatic). 
1H NMR (DMSO-d6)  9.14 
(br s, 1H, NH), 7.63 – 7.47 (m, 4H, H aromatic), 7.10 
(d, 2H, J=8.3 Hz, H-2,6 phenyl), 6.99 (d, 2H, J=8.3 Hz, 
H-3,5 phenyl), 6.87 (s, 1H, H imidazole), 5.11 (s, 2H, 
NCH2), 4.88 (s, 1H, HC4 DHP), 3.56 (s, 6H, OCH3), 
2.61  (t,  2H, J=8  Hz,  CH3CH2CH2),  2.22  (s,  6H,  CH3 
DHP), 1.46–1.14 (m, 4H, CH2), 0.83 ppm (t, 3H, J=7.3 
Hz,  CH3).  Anal.calcd.  for  C32H35N7O4:  C,  66.07;  H, 
6.06; N, 16.86. Found: C, 66.24; H, 6.18; N, 16.81. 
Dimethyl  1,  4-dihydro-2,  6-dimethyl-4-[2-n-propyl-1-
[2΄-(1H-tetrazole-5-yl)  biphenyl  -4-yl]  methyl] 
imidazole-5-yl]-3, 5-pyridinedicarboxylate (7a) 
A  solution  of  3a  (1.0  g,  1.6  mmoles),  methyl 
acetoacetate  (0.41  g,  3.6  mmoles)  and  ammonium 
hydroxide  25%  (0.6  mL)  in  methanol  (6  mL)  was 
reacted  according  to  the  method  described  in  second 
method for compound 5b. Purification  was done  with 
column chromatography (elution: chloroform-methanol 
95:5) to afford 7a in (0.38 g) 42% yield with mp 174 – 
176°C; IR (potassium bromide)  3400 (N-H), 3046 (C-
H, aromatic), 2950 (C-H, aliphatic), 1680 (C=O), 1490 
cm
-1 (C=C, aromatic). 
1H NMR (DMSO- d6)  9.16 (br 
s, 1H, NH), 7.59–7.38 (m, 4H, H aromatic), 7.07 (d, 2H, 
J=8.2 Hz, H-2,6 phenyl), 6.73 (d, 2H, J=8 Hz, H-3,5 
phenyl), 6.49 (s, 1H, H imidazole), 5.26 (s, 2H, NCH2), 
4.91 (s, 1H, HC4 DHP), 3.36 (s, 6H, OCH3), 2.33 (t, 2H, 
J=7.4 Hz, CH3 CH2CH2), 2.17 (s, 6H, CH3 DHP), 1.53–
1.41 (m, 2H, CH2), 0.81 ppm (t, 3H, J=7.3 Hz, CH3). 
Anal.calcd. for C31H33N7O4: C, 65.59; H, 5.86; N, 17.27. 
Found: C, 65.46; H, 5.94; N, 17.48. 
Diethyl 1, 4-dihydro-2, 6-dimethyl-4-[2-n-propyl-1-[2΄-
(1H-tetrazole-5-yl) biphenyl -4-yl] methyl] imidazole-5-
yl]-3, 5-pyridinedicarboxylate (7b) 
A solution of 3a (1.0 g, 1.6 mmoles), ethyl acetoacetate 
(0.47  g,  3.6  mmoles)  and  ammonium  hydroxide  25% 
(0.6 mL) in ethanol (6 mL) was reacted according to the 
method described in second method for compound 5b. 
Purification  was  done  with  column  chromatography 
(elution:  chloroform-methanol  95:5)  to  afford  7b  in 
(0.45  g)  47%  yield  with  mp  169  –  171  °C;  IR 
(potassium  bromide)    3450  (N-H),  3050  (C-H, 
aromatic), 2974 (C-H, aliphatic), 1676 (C=O), 1496cm
-1 
(C=C, aromatic). 
1H NMR (DMSO- d6)  9.08 (br s, 1H, 
NH), 7.70–7.40 (m, 4H, H aromatic), 7.05 (d, 2H, J=8.2 
Hz,  H-2,6  phenyl),  6.75  (d,  2H,  J=8.3  Hz,  H-3,5 
phenyl), 6.52 (s, 1H, H imidazole), 5.26 (s, 2H, NCH2), 
5.01 (s, 1H, HC4 DHP), 3.98–3.75 (m, 4H, OCH2), 2.32 
(t, 2H, J=7.4 Hz, CH3CH2CH2), 2.13 (s, 6H, CH3 DHP), 
1.49–1.29  (m,  2H,  CH2),  1.08  (t,  6H,  J=7  Hz, 
OCH2CH3),  0.79  ppm  (t,  3H,  J=7.4  Hz,  CH3). 
Anal.calcd. for C33H37N7O4: C, 66.54; H, 6.26; N, 16.46. 
Found: C, 66.61; H, 6.14; N, 16.32. 
Results and discussion 
2-alkylimidazole-4(5)-carboxaldehyde  derivatives  were 
prepared  according  to  procedure  described 
previously.
13,16,17 The N
1-alkylation of 2-alkylimidazole-
4(5)-carboxaldehydederivativeswithN-1-
(triphenylmethyl)-5-[4΄-(bromomethyl)biphenyl-2-yl] 
tetrazole afforded biphenyl imidazole regioisomers2 and 
3 in 1:2 ratio respectively (Scheme 1). The regioisomers 
were then separated using column chromatography.  
The  structures  of  regioisomers  were  confirmed  by 
1H 
NMR.  
1H NMR spectra of regioisomer 3 showed the 
benzylichydrogens  (N-CH2Ph)  were  more  deshielded 
(5.51  ppm)  than  benzylichydrogens  of  regioisomer  1 
(5.00 ppm).  
Using two methods described below, the final products 
were obtained in moderate yields.   
In  the  first  method,  trityl  protecting  group  was 
deprotected in acidic media (10% HCl solution), then 
classic  Hantzsch  reaction  was  performed  using  alkyl 
acetoacetate and 25% ammonium hydroxide solution to 
obtain the final dihydropyridine products (5a-d and 7a-
d)  in  moderate  yields.  Chemical  structures  of  the 
compounds were analyzed by 
1H NMR, infrared, mass 
spectroscopy and elemental analysis. Based on 
1H NMR 
of  compounds  5  and  7anddepending  on  the  type  of 
regioisomers,  protons  of    H-N,  H-C4,  OCH2CH3  and 
OCH3  on  1,4-dihydropyridines  were  appeared  within 
8.6-10.6  ppm  as  a    broad  singlet,  4.8-5.1  ppm  as  a 
singlet, 3.7-4.1 as multiplet and 3.4-3.6 ppm as a singlet 
respectively.  The  six  hydrogens  of  2,6-dimethyl-DHP 
are  appeared  as  a  singlet  in  2.2  ppm.  The 
1H  NMR 
spectrums corresponding to the methylene group on the 
carboethoxy substituent showed a rather more complex 
splitting pattern than a simple quartet. This behavior is 
due to existence of two diasterotopichydrogens of the 
methylene group. Similar splitting pattern for diethyl 4-
(nitroaryl)-1,4-dihydropyridine-3,5-dicarboxylate 
derivatives has been reported previously.
13,18 
In  addition,  mass  spectroscopy  analysis  of  5  and  7 
showed expectable fragmentation and hence established 
the structure of dihydropyridine derivatives. The Mass 
spectrum  fragmentation  pattern  of  compound  5a  is 
shown  in  Figure2  and  is  in  agreement  with  the 
suggested  structure.  Comparable  fragmentations  were 
previously  reported  for  some  dihydropyridine 
derivatives.
13,19-21  
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In the second method, trityl protected regioisomer2 or 3 
were subjected to classic Hantzsch reaction to afford the 
final analogs in moderate yields. 
1H NMR indicated that 
trityl  protective  group  was  removed  during  the 
dihydropyridine ring closure reaction, thereby avoiding 
addition step to remove the trityl protecting group. All 
aromatic  hydrogens  for  trityl  group  were  disappeared 
(6H at 6.98 ppm as di-doublet for H-ortho and 9H at 
7.52-7.25 ppm as multiple for H-meta and para).  
Thus,  the  second  method  was  concluded  to  be  more 
efficient than the first method since the deprotection and 
ring closure reaction occurs simultaneously in one pot. 
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Scheme 1. Condition of synthesis: i) K2CO3, DMF, room temperature and then isomer resolution; ii) first method: 1) HCl 10% to afford 
deprotected compound 4 and 6; 2) CH3COCO2R
2, NH3 25%, reflux; second method: CH3COCO2R
2, NH3 25%, reflux (deprotection and ring 
closure in one pot) 
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Figure 2. Proposed fragmentation pathways of compound 5a in mass spectroscopy 
Conclusion 
Eight  novel  dihydropridines  analogs  were  synthesized 
using classic Hantzsch condensation reaction. The key 
structural  elements  present  in  an  AT1  receptor 
antagonist (biphenyltetrazolyl imidazole)  were  merged 
with  key  structural  elements  in  calcium  channel 
blockers  (1,4-dihydropyridine)  to  afford  the  products 
with  potential  dual  activity  for  both  receptors.  The 
chemical  structures  of  novel  compounds  were 
confirmed  with 
1H  NMR  and  mass  spectroscopy 
analysis. The dihydropridines analogs were obtained by 
two  methods.  The  second  method  was  more  efficient 
than  the  fisrt  method  since  the  deprotection  and  ring 
closure reaction occurs simultaneously in one pot. 
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